By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Neurotrope 

10732 Hawk’s Vista Street

Plantation  Florida  33324  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS



Segment
Start Up





Company News
Neurotrope Issues Statement On Eli Lilly (LLY)'s Solanezumab 11/23/2016 9:04:45 AM
Neurotrope Completes Enrollment In Its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial Of Bryostatin In Patients With Moderate To Severe Alzheimer's Disease 11/22/2016 7:54:20 AM
Neurotrope Announces Private Placement of $20 Million 11/18/2016 7:30:51 AM
Dr. Daniel Alkon Appointed President Of Neurotrope 9/28/2016 7:24:08 AM
Neurotrope Names a New CEO 9/6/2016 6:52:32 AM
Neurotrope Submits An Amended Protocol To The FDA For Its Phase 2b Clinical Trial Of Its Lead Drug Candidate, Bryostatin-1, For The Treatment Of Advanced Alzheimer's Disease 8/15/2016 11:43:19 AM
Neurotrope Announces Changes To The Board Of Directors And Management 8/5/2016 7:19:09 AM
Neurotrope Announces That A New Study Published In The Journal of Biological Chemistry Shows That Bryostatin, A PKC Epsilon Activator, Generates New Synapses Through Accumulation Of The Synaptic Anchoring Protein PSD-95 At Neuronal Membranes 6/23/2016 6:52:00 AM
Neurotrope Taps Former Eli Lilly (LLY) Exec as New CMO 6/21/2016 6:43:47 AM
Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents At The Gordon Conference: Drugs That Target Common Mechanisms For Synaptic Restoration In Mental Retardation And Alzheimer's Disease 6/14/2016 11:31:27 AM
12345
//-->